Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
824 hedge funds and large institutions have $31.3B invested in Alexion Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 204 funds opening new positions, 241 increasing their positions, 284 reducing their positions, and 80 closing their positions.
156% more funds holding in top 10
Funds holding in top 10: 18 → 46 (+28)
155% more first-time investments, than exits
New positions opened: 204 | Existing positions closed: 80
38% more capital invested
Capital invested by funds: $22.6B → $31.3B (+$8.67B)
28% more call options, than puts
Call options by funds: $559M | Put options by funds: $436M
17% more funds holding
Funds holding: 707 → 824 (+117)
15% less repeat investments, than reductions
Existing positions increased: 241 | Existing positions reduced: 284
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$380M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$289M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$271M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
+$221M |
| 5 |
Millennium Management
New York
|
+$211M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$451M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$353M |
| 3 |
O
OrbiMed
New York
|
-$259M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$203M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$194M |
ALXN Hedge Fund Activity: Q4 2020 in Review
824 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2020, worth a combined $31.3B — up 38% from $22.6B a quarter earlier.
Buyers outnumbered sellers: 204 funds opened new ALXN positions and 80 closed out — a net gain of 124 holders — while 241 added to existing stakes and 284 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $380M. The largest seller was Fidelity Investments, cutting an estimated $451M.
- 824 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2020, up from 707 in Q3 2020.
- Funds reported $31.3B of Alexion Pharmaceuticals stock for Q4 2020, up 38% quarter-over-quarter.
- 204 funds opened new Alexion Pharmaceuticals positions in Q4 2020 and 80 closed out, a net change of +124 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2020 was Pentwater Capital Management, an estimated $380M added.
- The largest Alexion Pharmaceuticals seller in Q4 2020 was Fidelity Investments, an estimated $451M sold.
Based on aggregated 13F filings for Q4 2020.